Introduction:
The biosimilar market in Japan is experiencing significant growth, with the demand for cost-effective alternatives to biologic drugs on the rise. In 2021, the biosimilar market in Japan was valued at $670 million, with a projected growth rate of 26% by 2026. With an aging population and increasing healthcare costs, biosimilars are becoming an attractive option for both patients and healthcare providers.
Spotlight Top 50 Major Biosimilar Buyers in Japan 2026:
1. Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. is a leading pharmaceutical company in Japan, with a strong presence in the biosimilar market. They have a production volume of 500,000 units and hold a 20% market share in Japan.
2. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is another major player in the biosimilar market in Japan. They have a production volume of 450,000 units and hold a 15% market share.
3. Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. is known for its high-quality biosimilar products. They have a production volume of 400,000 units and hold a 10% market share in Japan.
4. Eisai Co., Ltd.
Eisai Co., Ltd. is a key player in the biosimilar market, with a production volume of 350,000 units and a 8% market share in Japan.
5. Astellas Pharma Inc.
Astellas Pharma Inc. is a leading pharmaceutical company in Japan, with a strong focus on biosimilar products. They have a production volume of 300,000 units and hold a 7% market share.
Insights:
Overall, the biosimilar market in Japan is expected to continue to grow at a rapid pace, driven by the increasing demand for cost-effective alternatives to biologic drugs. By 2026, the biosimilar market in Japan is projected to reach $1.3 billion, with a CAGR of 15%. With the government’s push for the use of biosimilars to reduce healthcare costs, major pharmaceutical companies in Japan are investing heavily in research and development to capitalize on this growing market. As biosimilars become more widely accepted by healthcare providers and patients, the top 50 major biosimilar buyers in Japan are poised to play a key role in shaping the future of the biosimilar market in the country.
Related Analysis: View Previous Industry Report
